Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.

[powerpress]

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of predictive biomarkers ERCC1 and RRM1 in advanced NSCLC.

[powerpress]

Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).

[powerpress]

Dr. George Simon, medical oncologist and Director of the Thoracic Oncology Program at Fox Chase Cancer Center in Philadelphia, has been kind enough to sit down for an interview with me earlier this year, which was made into a podcast several months ago.

“Are we theeeeere yet?” Every parent knows that familiar whining from the back seat of the car. Sometimes, I feel as impatient as the kid in the back of the car. Although EGFR mutation helps with predicting tarceva (erlotinib) response, I want markers for cytotoxic (traditional) chemotherapy now. Unlike the parent in the driver’s seat of the car, I’m not entirely sure where we are, or where we’re going. Sometimes I feel as though I’m driving in the dark. Could molecular markers be the headlights?